Replies to post #157078 on Avid Bioservices Inc (CDMO)

[EYEBUYSTOX]

I still see BTD for liver as an option. Assuming the FDA is swayed by the BP lobbyists, the expedited path to market in liver as a consolation to making PPHM go the long road in 2nd line lung allows most US BPs exploring PD-1 immontherapies (i.e. Nivolumab) to keep their profit streams and pipelines in the spotlight and going full speed ahead without hurting any of their potential market share for at least for another 1.5-2 years.

"Our studies show that sorafenib more than doubles the amount of the immunosuppressive molecule PS exposed on the blood vessels of HCC tumors," said Philip E. Thorpe, Ph.D., professor of pharmacology at UT Southwestern Medical Center, scientific adviser to Peregrine and inventor of the company's PS-targeting antibody technology. "These data suggest that the growth-blocking mechanisms of sorafenib combined with the vascular-targeting and immune-reactivation mechanisms of bavituximab may offer additive anti-tumor effects for patients with HCC."

http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=561859

There's a reason PPHM stopped focusing on pancreatic, stopped front-line lung, and has ignored doubling of MOS in breast for 2 years but has chosen to highlight liver. I think that bodes well for the upcoming results. Just my two cents.

And, for the record, I have a lot of respect for you. But sometimes your repeated over-use of exclamation points creates an irrational exuberance that might sway some readers to view your opinion as fact. Fewer !s and more ?s is the suggestion from your resident Debbie Downer.